Publications
RNA therapies for musculoskeletal conditions;
Mancino, C, Franke, M, Greco, A, Sontam, T, Mcculloch, P, Corbo, C & Taraballi, F 2025, , Journal of Controlled Release, vol. 377, pp. 756-766. https://doi.org/10.1016/j.jconrel.2024.11.057
Translational modeling-based evidence for enhanced efficacy of standard-of-care drugs in combination with anti-microRNA-155 in non-small-cell lung cancer;
Dogra, P, Shinglot, V, Ruiz-Ramírez, J, Cave, J, Butner, JD, Schiavone, C, Duda, DG, Kaseb, AO, Chung, C, Koay, EJ, Cristini, V, Ozpolat, B, Calin, GA & Wang, Z 2024, , Molecular Cancer, vol. 23, no. 1, 156. https://doi.org/10.1186/s12943-024-02060-5
Novel benzothiazole/benzothiazole thiazolidine-2,4-dione derivatives as potential FOXM1 inhibitors: In silico, synthesis, and in vitro studies;
Abusharkh, KAN, Comert Onder, F, Çinar, V, Onder, A, Sikik, M, Hamurcu, Z, Ozpolat, B & Ay, M 2024, , Archiv der Pharmazie, vol. 357, no. 12, 2400504. https://doi.org/10.1002/ardp.202400504
1034 Development of HLA class I expressing humanized patient-derived xenograft (hu-PDX) mouse models for the study of mRNA-based cancer vaccines in triple-negative breast cancer;
Chervo, MF, Qian, W, Ortega Martinez, KA, Zhou, J, Shroff, R, Mancino, C, Rojas, LG, Taraballi, F, Cooke, JP, Gollihar, JD & Chang, JC 2024, , J Immunother Cancer, vol. 12, no. Suppl 2, pp. A1155. https://doi.org/10.1136/jitc-2024-SITC2024.1034
Tissue-resident memory T cell abundance shaping non-small-cell lung cancer immune microenvironment and patient prognosis;
Shen, A, Chao, CC, Garrett, A, Liu, D, Zhu, Y, Mai, J & Jiang, C 2024, , Journal for immunotherapy of cancer, vol. 12, no. Suppl 2. https://doi.org/10.1136/jitc-2024-SITC2024.0180
Prophylactic and therapeutic cancer vaccine with continuous localized immunomodulation;
Kota, N, Gonzalez, DD, Liu, HC, Viswanath, D, Vander Pol, R, Wood, A, Di Trani, N, Chua, CYX & Grattoni, A 2024, , Nanomedicine: Nanotechnology, Biology, and Medicine, vol. 62, 102776. https://doi.org/10.1016/j.nano.2024.102776
Characterization of the Breast Cancer Liver Metastasis Microenvironment via Machine Learning Analysis of the Primary Tumor Microenvironment;
Goodin, DA, Chau, E, Zheng, J, OConnell, C, Tiwari, A, Xu, Y, Niravath, P, Chen, SH, Godin, B & Frieboes, HB 2024, , Cancer research communications, vol. 4, no. 10, pp. 2846-2857. https://doi.org/10.1158/2767-9764.CRC-24-0263
Use of novel platinum nanotherapeutics (Carrier-Pt) to eradicate chemoresistant epithelial ovarian cancer;
Liu, Y, Mai, J, Yu, D & Ramirez, PT 2024, , International Journal of Gynecological Cancer, vol. 34, no. Suppl 3, pp. A74-A75.
Adipocyte derived exosomes promote cell invasion and challenge paclitaxel efficacy in ovarian cancer;
Williams, ME, Howard, D, Donnelly, C, Izadi, F, Parra, JG, Pugh, M, Edwards, K, Lutchman-Sigh, K, Jones, S, Margarit, L, Francis, L, Conlan, RS, Taraballi, F & Gonzalez, D 2024, , Cell Communication and Signaling, vol. 22, no. 1, 443. https://doi.org/10.1186/s12964-024-01806-4
Novel platinum therapeutics induce rapid cancer cell death through triggering intracellular ROS storm;
Liu, Y, Yu, D, Ge, X, Huang, L, Pan, P-Y, Shen, H, Pettigrew, RI, Chen, S-H & Mai, J 2025, , Biomaterials, vol. 314, 122835. https://doi.org/10.1016/j.biomaterials.2024.122835